Study Objective: To determine, based on data from examination of apparently healthy subjects, parameter reference values for 18F-DOPA positron emission tomography (PET) of the brain. Study Design: This was a prospective study. Materials and Methods: Apparently healthy subjects (n = 33) underwent 18F-DOPA PET of the brain using a Discovery PET/CT 600 scanner. Data were processed using standard statistical methods. The Shapiro-Wilk test was used to test data distribution for normality, and Pearson and Spearman covariance and correlation matrices were calculated. The key components were analyzed to assess combined scattering (explained variance). Study Results: For absolute parameters, the following reference levels were determined for radioactivity concentration (median [1st quartile; 3rd quartile]): 2.24 [2.02; 2.80] kBq/mL in the right putamen, 2.26 [2.02; 2.75] kBq/mL in the left putamen, 2.11 [1.78; 2.55] kBq/mL in the right caudate nucleus (CN), 2.01 [1.74; 2.49] kBq/mL in the left caudate nucleus, and 0.81 [0.71; 1.00] and 0.81 [0.74; 1.02] kBq/mL in the right and left occipital cortices (OC), respectively. For relative parameters, the following reference values were determined (mean ± standard deviation): 2.66 ± 0.52 for the right corpus striatum/OC, 2.68 ± 0.53 for the left corpus striatum/OC, 2.36 ± 0.48 for the right CN/OC, 2.34 ± 0.47 for the left CN/OC, 1.09 ± 0.21 for the right corpus striatum/CN, and 1.11 ± 0.21 for the left corpus striatum/CN. Conclusion: The paper presents reference values for radioactivity concentration in 18F-DOPA PET of the brain. This is the first report of such data. Keywords: neurodegenerative disorders, dopamine metabolism, population norm.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.